Glow-in-the-Dark dyes reveal if IBD drugs hit their target
NCT ID NCT07258641
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether fluorescent dyes attached to two IBD drugs (adalimumab and risankizumab) can show where the drugs go in the gut. 30 adults with ulcerative colitis or Crohn's disease will receive a low dose of the labelled drugs, then undergo a special camera procedure 2-3 days later. The goal is to see if this imaging can predict who will respond to treatment, potentially avoiding ineffective therapies and their side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
fluorescently labelled adalimumab and risankizumab
What this could lead to
If successful, this could lead to a way to predict which IBD drug will work for a patient before starting treatment, reducing trial-and-error.
What could go wrong
This is an early-phase imaging study with only 30 participants. It tests feasibility, not treatment effectiveness, and the dyes are experimental. The approach may not translate into routine clinical use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS (UC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Medical Center Groningen
Groningen, Provincie Groningen, 9713GZ, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••